Bioelectronica Secures Series A Funding from Proxima Ventures and Co-win Ventures

(VCBeat) Feb. 13, 2021 -- Bioelectronica Corporation ("Bioelectronica"), a biotechnology company, recently announced the closing of an investment led by Proxima Ventures with participation from its angel round leader Co-win Ventures. The fresh round of funding will be used to expand the team and drive new applications in cell line development and antibody discovery for the Hypercell^® platform to enable the upgrade and rapid development of the custom assay system and the scalable microfluidic chip technology in the field of digital cell biology.

Bioelectronica is a research-stage biotechnology company building intelligent digital tools for drug discovery, cell screening, and cell sorting. Bioelectronica's platform combines computer vision, biochemical reagents and consumer electronics to speed discovery. They believe that by transforming biochemistry through digital innovation, they will fundamentally change the pace and price of therapeutic drug discovery and development.

Jonathan Hull, co-founder and chief executive of Bioelectronica, said, "I'm very glad to become partners with various investors, as we continue to develop and launch a proprietary single-cell sorting platform Hypercell^®. It uses computer vision, data science, and lens-free imaging technology to enable single-cell sorting assays with unprecedented throughput. With high-speed automation embedded in a computer vision single-cell sorting (CVSCS) system with proprietary algorithms and real-time analysis, Bioelectronica is able to accelerate the early identification of positive B-cell clones during antibody discovery and development. By improving workflow efficiency when deploying HyperCell ®, we have the potential to really enable R&D teams to build their product lines and patents at an unprecedented rate."

Shanghai-based Proxima Ventures invests in enterprises with innovative technologies that have tremendous potential to bring meaningful improvements to public health. With a large network of industry partners and networks with hospitals, Proxima Ventures' multidisciplinary team brings market intelligence to its investments, furthering growth and success of portfolio companies. 

Founded in 2009, Co-win Ventures is an angel and early-stage investor in TMT and Healthcare. They keep nurturing growth-stage companies graduated from their angel investment portfolio and our funds encompass the whole financial product chain, including seed funds, VC funds and PE funds. Co-win Ventures' business network covers China and the USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing, Shenzhen and Hong Kong.